HEALTH: Summary of Nov 15, 2026

By · Published on

Illustration of a virus particle
AI-generated illustration; does not depict the actual event.

The US loses its measles elimination status as deaths this year reach 10, WHO issues its first guidelines on type 1 diabetes in adults, early dupilumab is linked to less childhood asthma, an experimental blood test spots early breast cancer, and blood NAD levels track heart disease rather than age.

The US loses its measles elimination status as deaths this year reach 10

The United States has lost the measles elimination status it held for 26 years, after outbreaks kept the virus spreading across the country. The Pan American Health Organization, part of the World Health Organization, met this week to judge whether transmission had continued without a break for a full year, the test that cost Canada its own status last year. The decision follows warnings earlier this month that cases had reached their highest level since 1991.

The country’s measles death toll for the year climbed to 10 on Friday, when Pennsylvania and Wisconsin each reported a new death. Wisconsin said a child had died, while Pennsylvania said its latest victim was an unvaccinated resident of Montour County, bringing the state’s total to seven. Around 5,400 cases had been recorded nationwide by Thursday, more than double last year’s count, and at least four of the deaths were babies too young to be vaccinated.

Pennsylvania and Wisconsin now recommend an early vaccine dose for infants aged 6 to 11 months in areas with many cases. Two doses of the vaccine, normally given around a child’s first birthday and between the ages of 4 and 6, are 97% effective. The share of kindergarten pupils vaccinated against measles fell from 95% in the 2019-20 school year to 92% in 2025-26, and the disease had been declared eliminated from the country in 2000.


WHO issues its first guidelines on type 1 diabetes in adults

The World Health Organization has published its first guidelines on diagnosing and managing type 1 diabetes in adults, timed for World Diabetes Day, with advice meant to work in every setting, including poor, emergency and humanitarian ones. Around 9.5 million people were living with the condition worldwide in 2025, when a further 500,000 were diagnosed, and although it is often thought of as a childhood illness it increasingly affects adults.

The guidelines recommend several insulin injections a day, with doses adjusted to blood glucose, and describe human insulin, a manufactured version of the hormone, as an appropriate and effective choice. They call for regular glucose monitoring, through clinic blood tests, finger-prick checks or sensors worn on the skin, and suggest urine testing where blood testing is unavailable. Søren Brostrøm, the agency’s director for noncommunicable diseases, said many patients still lack affordable, high-quality insulin more than a century after its discovery.

The guidance supports WHO targets for all people with type 1 diabetes to have affordable insulin and blood glucose self-monitoring by 2030, and countries are urged to involve patients in designing their programmes. Type 1 diabetes is an autoimmune disease in which the immune system destroys the insulin-producing beta cells of the pancreas. Diabetes of all kinds affected 830 million people in 2022, more than 40% of whom did not know they had it, and the global burden has more than quadrupled since 1990.


Early dupilumab for an allergic swallowing disorder is linked to less childhood asthma

Young children treated with the biologic drug dupilumab for eosinophilic oesophagitis were less likely to develop asthma later than those given the steroid budesonide, according to a study presented at the annual scientific meeting of the American College of Allergy, Asthma and Immunology in Phoenix. The condition is an allergic disease of the oesophagus that can make eating difficult, causing some children to refuse food, vomit or grow poorly.

Immunologist Kayla Steinberger analysed health records from medical centres between 2016 and early 2026, comparing 344 children aged 6 or under who received dupilumab, an injection that blocks signals behind allergic inflammation, with 401 who swallowed budesonide. Asthma later developed in 10.5% of the dupilumab group against 16.2% of the budesonide group, and children on dupilumab had about half as many asthma diagnoses. The groups were matched for age, sex and eczema, and none had asthma beforehand.

The researchers stressed that the study shows a link rather than proof that the drug prevents asthma, and that studies following children over time are needed. Allergic conditions often appear in sequence as children grow, starting with eczema, then food allergies and later asthma, a pattern doctors call the allergic march. Dupilumab is approved for the oesophageal condition from the age of one, but for asthma only from six. The disease involves large numbers of white blood cells called eosinophils gathering in the oesophagus.


Experimental blood test spots early breast cancer and predicts its return

Israeli researchers have developed an experimental blood test that identified early-stage breast cancer with 95% accuracy and helped predict whether the disease would come back after treatment, according to a study published in Nature. The work, led by Efrat Shema’s group at the Weizmann Institute of Science and Guy Ron’s at the Hebrew University of Jerusalem with doctors at Kaplan Medical Centre in Rehovot, analyses epigenetic markers rather than relying only on genetic mutations.

The team first mapped the markers in tumours removed from 12 women, then measured dozens of them across millions of nucleosomes, fragments of DNA that dying cells release into the blood. Computer models trained on blood from 30 healthy women and 77 patients whom the Mayo Clinic in Florida had tracked for five years or more detected tumours of no more than 2cm, and performance held across breast densities and cancer types when the sample grew to 188.

The researchers also found a rare group of highly aggressive cells inside tumours not thought to be aggressive, and the more of their signature in the blood, the higher the risk of recurrence; combined with other markers, it separated patients whose cancer returned from those whose did not with 81% accuracy. Breast cancer returns in 20% to 40% of cases even after apparently successful treatment. Such blood tests, known as liquid biopsies, are already used to guide treatment for some patients.


Blood NAD levels track heart disease rather than age, study finds

Blood levels of NAD, a molecule at the centre of the boom in anti-ageing supplements, do not fall with age in healthy adults but are markedly lower in people with cardiovascular disease, especially high blood pressure, according to a study of 1,068 adults by researchers at Vilnius University in Lithuania. The findings, published in Nature Metabolism, challenge the common belief that declining NAD in the blood is a natural part of growing older.

The team made 1,340 measurements from dried blood spots collected under standard conditions. Among healthy participants, levels stayed stable in men and rose slightly in women, while people with chronic illness had lower levels, most clearly those with hypertension. Dalius Ratautas, who led the research, said the results raised the question of whether NAD could reveal something about heart health, although the study does not show cause and effect or that supplements help.

Animal studies had reported falling NAD in tissues such as muscle, brain and skin, fuelling interest in supplements such as nicotinamide mononucleotide and nicotinamide riboside. In a commentary alongside the study, Stephen Gardell and Joseph Baur noted that blood levels, mostly from red blood cells, may not reflect those in other tissues. The coenzyme was first identified in 1906 by the British biochemists Arthur Harden and William John Young, and the researchers now plan to test whether blood NAD predicts cardiovascular risk.

In this topic